Progress and Prospects in Parkinson's Research/Therapy/Neuroprotection/Probuool
Probucol is a lipid-lowering phenolic compound with anti-inflammatory and antioxidant properties that has been recently reported as protective in neurotoxicity and neurodegeneration models.
Research
[edit | edit source]2013
Ribeiro et al[1]tested the efficacy of the drug. Swiss mice were treated with probucol during 21 days (11.8 mg/kg; oral route). Two weeks after the beginning of treatment, mice received a single intracerebroventricular (i.c.v.) infusion of 6-hydroxydopamine (6-OHDA).
On the 21st day, locomotor performance, striatal oxidative stress-related parameters, and striatal tyrosine hydroxylase and synaptophysin levels, were measured as outcomes of toxicity. 6-OHDA-infused mice showed hyperlocomotion and a significant decrease in striatal tyrosine hydroxylase (TH) and synaptophysin levels. In addition, 6-OHDA-infused mice showed reduced superoxide dismutase activity and increased lipid peroxidation and catalase activity in the striatum.
Further Reading
[edit | edit source]Today
Use the following links to query the PubMed, PubMed Central and Google Scholar databases using the Search terms:- Parkinson's_Disease Probucol.
This will list the latest papers on this topic. You are invited to update this page to reflect such recent results, pointing out their significance.
References
[edit | edit source]<references>
- ↑ Ribeiro, R.P.; Moreira, E.L; Santos, D.B,.; Colle, D.; Dos Santos, A.A.; Peres, K.C.; Figueiredo, C.P. and Farina, M. (2013)@ Abstract Neurochem. Res. 2013 Jan 19. Probucol Affords Neuroprotection in a 6-OHDA Mouse Model of Parkinson's Disease. http://www.ncbi.nlm.nih.gov/pubmed/23334712